LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
äŒæ¥ã³ãŒãLIVN
äŒç€ŸåLivaNova PLC
äžå Žæ¥Oct 19, 2015
æé«çµå¶è²¬ä»»è
ãCEOãMakatsaria (Vladimir A)
åŸæ¥å¡æ°2900
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Oct 19
æ¬ç€Ÿæåšå°20 Eastbourne Terrace
éœåžLONDON
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited Kingdom
éµäŸ¿çªå·W2 6LG
é»è©±çªå·442033250662
ãŠã§ããµã€ãhttps://www.livanova.com/
äŒæ¥ã³ãŒãLIVN
äžå Žæ¥Oct 19, 2015
æé«çµå¶è²¬ä»»è
ãCEOãMakatsaria (Vladimir A)